• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?

作者信息

Chakraborty Rajshekhar, Lentzsch Suzanne

机构信息

Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.

出版信息

J Clin Oncol. 2022 Sep 20;40(27):3099-3102. doi: 10.1200/JCO.22.01040. Epub 2022 Jun 27.

DOI:10.1200/JCO.22.01040
PMID:35759726
Abstract
摘要

相似文献

1
Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?循环肿瘤细胞负荷作为多发性骨髓瘤分期的一个组成部分：准备好进入黄金时代了吗？
J Clin Oncol. 2022 Sep 20;40(27):3099-3102. doi: 10.1200/JCO.22.01040. Epub 2022 Jun 27.
2
Prognostic and predictive biomarker developments in multiple myeloma.多发性骨髓瘤的预后和预测生物标志物的发展。
J Hematol Oncol. 2021 Sep 23;14(1):151. doi: 10.1186/s13045-021-01162-7.
3
Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤中循环克隆浆细胞的预后价值。
Hematology. 2021 Dec;26(1):510-517. doi: 10.1080/16078454.2021.1948208.
4
A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.一种不依赖CD138检测多发性骨髓瘤微小残留病和循环肿瘤细胞的策略。
Br J Haematol. 2016 Apr;173(1):70-81. doi: 10.1111/bjh.13927. Epub 2016 Jan 5.
5
Should we be routinely testing for circulating clonal plasma cells in patients with multiple myeloma?我们是否应该对多发性骨髓瘤患者常规检测循环克隆性浆细胞？
Cytometry B Clin Cytom. 2018 Sep;94(5):559. doi: 10.1002/cyto.b.21741.
6
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.循环肿瘤细胞用于多发性骨髓瘤的全面和多区域非侵入性遗传特征分析。
Leukemia. 2020 Nov;34(11):3007-3018. doi: 10.1038/s41375-020-0883-0. Epub 2020 Jun 1.
7
Circulating plasma cells with Russell bodies in osteosclerotic myeloma.骨硬化性骨髓瘤中带有拉塞尔小体的循环浆细胞。
Blood. 2013 Jul 11;122(2):160. doi: 10.1182/blood-2013-01-479154.
8
Relevant prognostic features of multiple myeloma and the new International Staging System.多发性骨髓瘤的相关预后特征及新的国际分期系统
Leuk Lymphoma. 2007 Mar;48(3):458-68. doi: 10.1080/10428190601059753.
9
Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.应用免疫磁珠联合流式细胞术富集循环骨髓瘤细胞监测多发性骨髓瘤患者微小残留病和复发。
Ann Hematol. 2019 Dec;98(12):2769-2780. doi: 10.1007/s00277-019-03833-5. Epub 2019 Nov 20.
10
Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.通过对循环骨髓瘤细胞和游离骨髓瘤DNA的V(D)J重排进行二代测序来监测多发性骨髓瘤。
Haematologica. 2017 Jun;102(6):1105-1111. doi: 10.3324/haematol.2016.161414. Epub 2017 Feb 9.

引用本文的文献

1
Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia.基于外周血流式细胞术的浆细胞白血病定义
Leukemia. 2025 May 26. doi: 10.1038/s41375-025-02653-z.
2
Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study.新诊断多发性骨髓瘤中循环肿瘤细胞≥2%的临床结局：一项多中心研究的见解
Ann Med. 2025 Dec;57(1):2496796. doi: 10.1080/07853890.2025.2496796. Epub 2025 Apr 30.
3
A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms.
循环肿瘤浆细胞的病理生物学综述：浆细胞肿瘤预后不良的必要条件。
Oncol Res. 2025 Apr 18;33(5):1055-1068. doi: 10.32604/or.2024.055154. eCollection 2025.
4
Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions.唾液腺癌靶向治疗和全身治疗的进展：当前选择与未来方向
Curr Oncol. 2025 Apr 16;32(4):232. doi: 10.3390/curroncol32040232.
5
A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival.中国乳腺癌患者循环肿瘤细胞的真实世界比较：新型设备、循环肿瘤细胞计数及其总生存期
Heliyon. 2024 Apr 3;10(7):e29217. doi: 10.1016/j.heliyon.2024.e29217. eCollection 2024 Apr 15.
6
Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant.未计划进行前期移植的多发性骨髓瘤患者循环肿瘤浆细胞及外周血可测量残留病评估
Hemasphere. 2024 Apr 1;8(4):e63. doi: 10.1002/hem3.63. eCollection 2024 Apr.
7
Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma.不适合移植的多发性骨髓瘤患者基线循环肿瘤细胞与 PET/CT 检查结果的分析。
Blood Adv. 2024 Jan 9;8(1):37-46. doi: 10.1182/bloodadvances.2023011890.
8
Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients.影响乳腺癌循环肿瘤细胞诊断和预后价值的因素：对8935例患者的荟萃分析
Front Oncol. 2023 Nov 27;13:1272788. doi: 10.3389/fonc.2023.1272788. eCollection 2023.
9
More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.超过2%的循环浆细胞作为一大群新诊断多发性骨髓瘤患者的预后生物标志物。
Ann Hematol. 2023 Oct;102(10):2943-2945. doi: 10.1007/s00277-023-05362-8. Epub 2023 Jul 12.
10
"Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.下一代流式细胞术评估多发性骨髓瘤可测量/微小残留病的“朋友与敌人”
Front Oncol. 2022 Nov 28;12:1057713. doi: 10.3389/fonc.2022.1057713. eCollection 2022.